Omnicell’s (OMCL) Buy Rating Reaffirmed at Benchmark

Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating reissued by Benchmark in a report released on Tuesday,Benzinga reports. They currently have a $62.00 price target on the stock. Benchmark’s price target indicates a potential upside of 43.60% from the stock’s current price.

A number of other equities research analysts also recently commented on OMCL. Barclays lifted their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Craig Hallum lifted their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus target price of $52.33.

Omnicell Trading Down 0.6 %

Shares of NASDAQ:OMCL traded down $0.24 on Tuesday, hitting $43.18. 21,313 shares of the company were exchanged, compared to its average volume of 308,442. The firm has a market capitalization of $2.00 billion, a P/E ratio of -111.43, a price-to-earnings-growth ratio of 30.78 and a beta of 0.78. The stock’s 50 day moving average price is $44.69 and its 200 day moving average price is $42.99. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74.

Insider Activity at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.64% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Van ECK Associates Corp grew its holdings in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after buying an additional 315 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after purchasing an additional 355 shares during the period. KBC Group NV grew its holdings in shares of Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after purchasing an additional 778 shares during the period. Finally, 1620 Investment Advisors Inc. grew its holdings in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.